Steve Pakola, serving as the Chief Medical Officer at REGENXBIO Inc. (NASDAQ:RGNX), completed a transaction disposing of 2,161 shares of the company's common stock on July 2, 2026. The total value of the shares sold was $29,476, executed at a price of $13.64 per share. This sale was facilitated through a Rule 10b5-1 trading plan, which allows executives to pre-arrange stock transactions to avoid potential conflicts of interest.
Concurrently with the sale, Mr. Pakola exercised stock options to acquire an identical number of shares, 2,161, at a cost of $7.86 per share, totaling $16,985. These options were part of a broader grant structure where 25% of the shares vested on January 2, 2026, with the remaining balance vesting in equal monthly installments over the following 36 months, contingent upon continuous service to the issuer. Following this exercise, Mr. Pakola's derivative holdings, specifically stock options, stand at 64,812 shares. His direct ownership of common stock post-transaction remains at 213,009 shares.
The transaction occurs against a backdrop of significant operational developments for REGENXBIO. The company recently announced the dosing of the first patient in its Phase IIb/III NAAVIGATE trial targeting diabetic retinopathy. This milestone triggers a $100 million payment from AbbVie. Additionally, REGENXBIO has completed dosing in its confirmatory study for RGX-202, a gene therapy for Duchenne muscular dystrophy, ahead of the planned schedule. The firm intends to submit a Biologics License Application (BLA) under the accelerated approval pathway by the third quarter of 2026.
Regulatory progress also includes alignment with the FDA regarding the resubmission of the BLA for NAVSUNLI for Mucopolysaccharidosis II. The FDA has acknowledged that existing clinical data are sufficient for consideration under the accelerated approval pathway. H.C. Wainwright has reiterated its Buy rating for REGENXBIO, maintaining a price target of $26.00, citing these trial milestones and regulatory updates.
Despite these advancements, market analysis presents a contrasting view. InvestingPro analysis suggests the stock appears overvalued relative to its Fair Value, placing it among companies on the Most Overvalued list. One of 13 InvestingPro Tips highlights that REGENXBIO is quickly burning through cash, a key consideration for investors evaluating the biotech's financial runway. The stock has seen a 52% gain over the past year, trading at $14.83, up from previous levels, though valuation models indicate caution.